Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings

By sjmartinez • June 19, 2023

Foeldvari I, Torok KS, Klotsche J, Anton J, Reis PC, Del Gado F, Denton C, Hinrichs B, Li SC, Pain C, Pilkington C, Cutolo M, Kasapcopur O, Khanna D, Ruperto N, Smith V, Furst DE. Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings. Arthritis Care Res (Hoboken). 2023 Jun 18. doi: 10.1002/acr.25171. Epub ahead of print. PMID: 37332054.

Tags: Publications, Rheumatology

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]